Zacks Research Has Bullish Forecast for BMRN Q1 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research boosted their Q1 2025 earnings estimates for shares of BioMarin Pharmaceutical in a note issued to investors on Wednesday, March 12th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $0.69 for the quarter, up from their previous forecast of $0.61. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $3.30 EPS, Q1 2026 earnings at $0.91 EPS, Q3 2026 earnings at $1.07 EPS, Q4 2026 earnings at $1.16 EPS and FY2026 earnings at $4.12 EPS.

A number of other analysts also recently issued reports on BMRN. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Bank of America upped their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price objective on the stock in a report on Monday, February 24th. Citigroup boosted their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

BioMarin Pharmaceutical Stock Up 0.4 %

BMRN traded up $0.28 during trading on Monday, reaching $71.60. The company had a trading volume of 500,279 shares, compared to its average volume of 1,769,581. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. BioMarin Pharmaceutical has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a market cap of $13.66 billion, a P/E ratio of 32.55, a PEG ratio of 0.61 and a beta of 0.33. The business's fifty day moving average price is $66.44 and its 200 day moving average price is $68.40.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million.

Insiders Place Their Bets

In related news, CAO Erin Burkhart sold 1,344 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the transaction, the chief accounting officer now directly owns 13,105 shares in the company, valued at $896,119.90. This trade represents a 9.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.85% of the company's stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several large investors have recently bought and sold shares of the stock. Merit Financial Group LLC bought a new position in BioMarin Pharmaceutical in the 4th quarter worth about $317,000. Assenagon Asset Management S.A. increased its stake in shares of BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after buying an additional 502,695 shares during the period. Wedmont Private Capital purchased a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $430,000. Swedbank AB grew its stake in BioMarin Pharmaceutical by 11.2% in the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares during the period. Finally, EULAV Asset Management grew its stake in BioMarin Pharmaceutical by 12.9% in the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company's stock worth $9,208,000 after purchasing an additional 15,000 shares during the period. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.